ReviewNature reviews. Urology2010
Lymphotropic nanoparticle enhanced MRI for the staging of genitourinary tumors.
Review in Nature reviews. Urology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Defining risk of micrometastatic disease and tumor recurrence in patients with stage I testicular germ cell tumors.Translational andrology and urology · 2020Review
- Lymph node imaging in testicular cancer.Translational andrology and urology · 2018Review
- Magnetic nanoformulations for prostate cancer.Drug discovery today · 2017Review
- Towards clinically translatableNature reviews. Materials · 2017Article
- Magnetic nanoparticles for precision oncology: theranostic magnetic iron oxide nanoparticles for image-guided and targeted cancer therapy.Nanomedicine (London, England) · 2017Review
- Nanoparticle-Based Magnetic Resonance Imaging on Tumor-Associated Macrophages and Inflammation.Frontiers in immunology · 2017Review
- Diagnosis of prostate cancer via nanotechnological approach.International journal of nanomedicine · 2015Review
- Imaging macrophages with nanoparticles.Nature materials · 2014Review
- Effect of ligand density, receptor density, and nanoparticle size on cell targeting.Nanomedicine : nanotechnology, biology, and medicine · 2013Article
- Preclinical lymphatic imaging.Molecular imaging and biology · 2011Review
- Controlled self-assembling of gadolinium nanoparticles as smart molecular magnetic resonance imaging contrast agents.Angewandte Chemie (International ed. in English) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanotechnology is poised to have a substantial influence on biomedicine. A unique example of a nanotechnology that has progressed from proof-of-concept to human clinical trials is the use of ultrasmall superparamagnetic iron oxide nanoparticles as a cell-specific contrast agent for MRI. When injected systemically, these particles are taken up by macrophages of the reticuloendothelial system and accumulate in lymph nodes. This passive, cell-specific targeting of the iron oxide nanoparticles to lymph nodes, and the differential cellular content of benign versus malignantly infiltrated nodes make this method suitable for cancer staging. By using lymphotropic nanoparticle enhanced MRI, differences in benign versus malignant infiltration of lymph nodes can be visualized, which adds accuracy to standard MRI beyond criteria based solely upon the size and shape of lymph nodes. This technology has been used to assess lymph node metastases in a large number of human cancer types. In this Review, we focus on lymphotropic nanoparticle enhanced MRI and its application for the staging of genitourinary malignancies.
Indexed as
Identifiers
20084078What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.